Join to View Full Profile
400 Parnassus AveFl 4San Francisco, CA 94143
Phone+1 415-353-9364
Fax+1 415-353-6370
Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
New York University School of MedicineClass of 2002
Certifications & Licensure
CA State Medical License 2016 - 2026
TX State Medical License 2007 - 2017
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015
Clinical Trials
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma Start of enrollment: 2022 Jan 05
Roles: Contact
Publications & Presentations
PubMed
- 2 citationsUrine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.Rahul Banerjee, Amber R Fritz, Othman S Akhtar, Ciara L Freeman, Andrew J Cowan
Leukemia. 2025-04-01 - 35 citationsDaratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.Ashraf Badros, Laahn Foster, Larry D Anderson Jr, Chakra P Chaulagain, Erin Pettijohn
Blood. 2025-01-16 - 1 citationsA plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed mul...Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves
Future Oncology. 2025-01-01
Journal Articles
- Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction DrugsKrina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
Abstracts/Posters
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell TherapyNina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...Nina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Breaking the Glass Ceiling of Age in Transplant in Multiple MyelomaNina D. Shah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Immunotherapy in Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autolo...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
- CAR T-cell Therapy Produces Deep, Sustained Remissions in Patients with Relapsed MyelomaFebruary 24th, 2021
- Dr. Shah Discusses Data on Ide-Cel and Melflufen, Both Granted Priority Review by FDAOctober 23rd, 2020
New Class of Drug Appears to Extend Survival in Patients with Triple-Refractory Multiple MyelomaJuly 30th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
